European MedTech valuation multiples - September 2025

European MedTech valuation multiples are showing a cautious but positive trend, driven by a combination of technological innovation, strategic M&A activity and an improving economic outlook. Here's a breakdown of the key valuation multiples and the factors influencing them as of September 2025:

Key Valuation Multiples

Average Revenue Multiples (EV/Revenue): The general range for HealthTech companies is 4x-6x revenue.However, this can vary significantly based on the company's profile.

Highly innovative segments like AI-driven solutions, telehealth platforms, and advanced analytics are commanding premium valuations, with multiples reaching 6x-8x revenue or more. This is due to strong buyer interest from pharmaceuticals, hospitals, and private equity firms willing to pay for cutting-edge technology and future revenue potential.

Companies focused on value-based care models or with robust data monetization capabilities are also seeing a premium, often valued between 5.5x-7x revenue.

Smaller or unprofitable startups typically face valuation compression, with multiples in the 3x-4x range.

Average EBITDA Multiples (EV/EBITDA): For profitable MedTech companies, the Enterprise Value (EV) to EBITDA multiples are generally observed between 10x-14x. This is a slight increase from the 10x-12.5x range seen in 2024, reflecting a growing, albeit cautious, optimism in the market for profitable entities.

Drivers of Valuation

Several factors are influencing these valuation multiples:

Dominance of AI and Digital Health: AI is the single biggest driver of valuation premiums. Investors and strategic buyers are focusing on companies with proprietary AI algorithms for diagnostics, drug discovery, or patient care. They are particularly interested in solutions that have been clinically validated and are deeply integrated into existing clinical workflows, creating "workflow lock-in."

A Maturing Regulatory Environment: The implementation of regulations like the EU AI Act and the European Health Data Space (EHDS) is providing more clarity for investors, which reduces risk and boosts confidence. This is a significant factor in attracting more investment.

Favourable Economic and Demographic Trends: Europe's aging population and the increasing prevalence of chronic diseases are creating a stable and growing demand for MedTech solutions. Furthermore, the shift from a "fee-for-service" to a "value-based care" model is rewarding companies that can demonstrate measurable cost savings and improved patient outcomes.

M&A and Private Equity Activity: The European MedTech market is experiencing a significant surge in M&A activity. Private equity firms, with substantial "dry powder" (unallocated capital), are actively seeking high-quality companies, which increases competition and pushes up valuations.

Large MedTech and biopharma companies are also acquiring smaller, innovative firms to consolidate market share and expand their portfolios. While the number of deals may have slightly decreased, the total value of these deals has surged, indicating a focus on larger, more substantial acquisitions of mature companies.

To discuss how Nelson Advisors can help your HealthTech, MedTech or Digital Health company, please email [email protected]